ArticleFrontiers in immunology2023

Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children-the Polish Pediatric Leukemia and Lymphoma Study Group experience.

Katarzyna Pawinska-Wasikowska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.